Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing a novel class of precision immuno-oncology therapeutics. Janux's platform masking technology is used to engineer unique immunotherapies with the potential to generate tumor-specific immune responses, attacking and killing tumors without destroying healthy tissue. Their primary focus is on activating T cells within the tumor microenvironment, leveraging their proprietary tumor activated T cell engager (TRACTr) and tumor activated immunomodulator (TRACIr) platforms.

The company is committed to providing cancer patients with safe and effective drugs that direct and guide their immune system to eradicate tumors. Janux's mission is to address critical unmet needs in the treatment of cancer by creating therapies with a high therapeutic index—maximizing potency while minimizing toxicity. Janux successfully closed their initial public offering (IPO) in June of 2021, demonstrating their commitment to bringing innovative solutions to patients in need.

Janux Therapeutics offers a flexible schedule as a benefit for its employees. While on-site work is required in San Diego, the specific schedule can be arranged to best suit the employee's needs. This indicates a potential for flexible start and end times or the possibility of some remote work arrangements.

Janux Therapeutics offers a comprehensive benefits package that includes medical, dental, and vision insurance, as well as supplemental disability insurance, 401K matching, a stock purchase plan, and a targeted annual bonus. Employees also enjoy a flexible schedule, life insurance, and generous vacation and sick time.

Janux Therapeutics is a clinical-stage company focused on developing unique, next-generation immunotherapies to address critical unmet needs in the treatment of cancer. Their mission is to provide cancer patients with safe and effective drugs that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Janux utilizes its proprietary tumor-activated discovery platform to develop product candidates designed to generate tumor-specific immune responses, focusing T cells to attack the cancer while limiting toxicity elsewhere in the body.

Janux Therapeutics fosters a collaborative and inclusive culture that prioritizes scientific integrity and teamwork. The company values data-driven decision making, scientific creativity, and a shared commitment to developing innovative cancer therapies that improve patients' lives. Janux encourages a team mentality where individuals are valued and given opportunities to grow, and promotes a healthy work-life balance for employees.

Janux Therapeutics emphasizes attracting, hiring, and retaining a diverse and inclusive workforce. They prioritize building a team mentality that celebrates understanding, respect, and appreciation for diverse viewpoints, expertise, and experiences for all individuals within the company. Janux is committed to providing a work environment free of harassment and discrimination based upon a protected category and an environment free from retaliation for protected activity.